Fehrenbacher Fehrenbacher L L Cecchini Cecchini RS RS Geyer Geyer CE CE NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2 NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2 J Clin Oncol J Clin Oncol 2020 2020 38 38 5 5 444 444 453 453 10.1200/JCO.19.01455 10.1200/JCO.19.01455 supplied-pmid 31821109? Here, ERBB2 is linked to invasive breast carcinoma.